TOTAL VOLUME:
$114.4b
24H VOL:
$84,940,147
24H TRANSACTIONS:
1,362,287,844
OPEN INTEREST:
$1,163,022,755
334,261
Markets across
33,310
events
MATCHED EVENTS:
4,574
PLATFORM COVERAGE:
5
Polymarket:
42%
VS.
Kalshi:
58%
Before Oct 1, 2026
- Kalshi
Before Oct 1, 2026 - Kalshi
1W
News
Positive
Negative
Neutral
Hover marker for details
Vol.
·
Resolves Jan 8, 2028
Latest in Science and Technology
Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Oct 1, 2026?
$
Description
Camizestrant is an experimental estrogen receptor degrader being developed to treat hormone receptor-positive, HER2-negative advanced breast cancer in patients with ESR1 mutations, which are associated with resistance to standard endocrine therapies. The market tracks whether the FDA will approve this drug for this specific indication across multiple time windows through January 2028.
Kalshi
FDA approval of camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation triggers a Yes resolution, with approval defined as issuance of an approval letter for a New Drug Application (NDA), Biologics License Application (BLA), or supplemental application (sNDA/sBLA) for the specified indication. Qualifying approvals include standard approval, accelerated approval based on surrogate endpoints, and approval with Risk Evaluation and Mitigation Strategy (REMS) or restricted distribution, provided such restrictions do not limit approval to compassionate use or expanded access only. Complete Response Letters, approvable letters requiring additional actions, tentative approvals, Emergency Use Authorization without full approval, and approvals limited to export or non-U.S. use do not constitute qualifying approvals. If a Complete Response Letter is issued, the market resolves to No unless the sponsor subsequently obtains full approval after addressing FDA concerns within the applicable deadline. An Advisory Committee vote against approval does not prevent a Yes resolution if the FDA approves the drug anyway. Accelerated approvals that are later withdrawn still count as approvals if the initial accelerated approval occurred after market issuance. Sponsor withdrawal of the application before FDA action results in immediate No resolution. The market operates across five sequential time windows: June 1, 2026; July 1, 2026; October 1, 2026; January 1, 2027; and January 1, 2028.
Frequently asked questions
Prediction markets aggregate real-time trader expectations, often reflecting information faster than traditional analyst reports. While pharmaceutical analysts publish periodic forecasts on camizestrant's regulatory pathway and clinical data, this market captures dynamic consensus as new trial results, FDA communications, or competitive developments emerge. Comparing odds here to published analyst estimates can reveal whether the market is pricing in optimism or caution relative to expert opinion on advanced breast cancer treatment approvals.
On Kalshi, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. On Kalshi, this market is priced as a binary contract reflecting the probability of FDA approval for camizestrant in advanced breast cancer. Traders buy or sell shares representing yes or no outcomes, with the contract price directly corresponding to the implied approval probability. As new clinical or regulatory information surfaces, the price adjusts to reflect updated market expectations, allowing participants to enter or exit positions based on their own assessment of the approval timeline and likelihood.
This market resolves on Jan 8, 2028. The outcome will be determined by whether the FDA grants approval for camizestrant as a treatment for advanced breast cancer by that date. Traders should monitor FDA announcements, clinical trial milestones, and regulatory communications leading up to resolution to stay informed on the approval status.
Key catalysts include announcements of Phase 3 trial results for camizestrant in advanced breast cancer, FDA feedback letters or meeting outcomes, competitive approvals in the same therapeutic area, and regulatory guidance on approval timelines. Safety or efficacy data presented at major oncology conferences could also shift trader sentiment. Additionally, changes in FDA staffing, priority review designations, or shifts in the broader regulatory environment for hormone receptor-positive breast cancer treatments may influence market pricing before resolution.
